Bavarian Nordic A/S (CPH:BAVA)
Denmark
· Delayed Price · Currency is DKK 158.60
-7.95 (-4.77%)
May 13, 2025, 4:59 PM CET
Bavarian Nordic Revenue
Bavarian Nordic had revenue of 1.35B DKK in the quarter ending March 31, 2025, with 61.95% growth. This brings the company's revenue in the last twelve months to 6.23B, down -6.18% year-over-year. In the year 2024, Bavarian Nordic had annual revenue of 5.72B, down -19.06%.
Revenue (ttm)
6.23B
Revenue Growth
-6.18%
P/S Ratio
2.08
Revenue / Employee
3.79M
Employees
1,605
Market Cap
12.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.72B | -1.35B | -19.06% |
| Dec 31, 2023 | 7.06B | 3.91B | 124.14% |
| Dec 31, 2022 | 3.15B | 1.25B | 66.02% |
| Dec 31, 2021 | 1.90B | 45.49M | 2.46% |
| Dec 31, 2020 | 1.85B | 1.19B | 179.61% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 303.14B |
| Coloplast | 27.79B |
| Genmab | 21.64B |
| Demant | 22.42B |
| ALK-Abelló | 5.71B |
| Zealand Pharma | 55.69M |
| H. Lundbeck | 22.00B |
| Ambu A/S | 5.83B |
Bavarian Nordic News
- 3 days ago - Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such - GlobeNewsWire
- 4 days ago - Bavarian Nordic A/S 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 4 days ago - Bavarian Nordic A/S reports interim Q1 results - Seeking Alpha
- 4 days ago - Bavarian Nordic Announces Interim Results for the First Three Months of 2025 - GlobeNewsWire
- 7 days ago - Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines - GlobeNewsWire
- 11 days ago - Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom - GlobeNewsWire
- 26 days ago - Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP) - GlobeNewsWire